ArticleFrontiers in oncology2026
UAP1 as a prognostic biomarker regulating malignant biological functions in multiple myeloma cells.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Multiple myeloma (MM) is a hematological malignancy characterized by proliferation of malignant plasma cells. UDP-N-acetylglucosamine pyrophosphorylase 1 (UAP1) has been shown to promote progression in various cancers. However, its specific role in MM remains unclear. Methods: We analyzed six datasets comprising 3,117 patients from the Multiple Myeloma Research Foundation and Gene Expression Omnibus databases. The reliability of UAP1 as a prognostic predictor was also systematically evaluated. To further elucidate the specific mechanisms underlying the role of UAP1 in promoting MM progression, we performed an in-depth analysis of single-cell RNA sequencing data from 24 patients with MM. Additionally, we evaluated UAP1's therapeutic potential using two MM cell lines (RPMI-8226 and U266). Results: Across all 3,117 patients with MM, high UAP1 expression correlated with significantly worse overall survival, event-free survival, and progression-free survival. Patients with high UAP1 expression consistently exhibited concurrent genetic abnormalities. Single-cell data suggest that UAP1 is predominantly expressed in tumor cells, is closely associated with tumor cell differentiation signatures, and shows a correlative link with the expression of immunosuppressive pathway components. Conclusions: UAP1 expression is significantly correlated with tumor differentiation, proliferation, immunosuppression, and patient prognosis, establishing it as an prognostic biomarker Regulating Malignant Biological Functions in Multiple Myeloma Cells. Our findings may guide the development of novel treatment strategies and improve clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.